S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Genprex Stock Forecast, Price & News

-0.01 (-0.72%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
1,726 shs
Average Volume
98,200 shs
Market Capitalization
$66.10 million
P/E Ratio
Dividend Yield
Price Target

Genprex MarketRank™ Forecast

Analyst Rating
Short Interest
3.82% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.27mentions of Genprex in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.42) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.28 out of 5 stars

Medical Sector

1054th out of 1,428 stocks

Pharmaceutical Preparations Industry

516th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

Genprex logo

About Genprex (NASDAQ:GNPX) Stock

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX Stock News Headlines

Genprex (NASDAQ:GNPX) Shares Up 3.6%
Genprex, Inc. (GNPX)
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.86 per share


Free Float
Market Cap
$66.10 million
Not Optionable

Genprex Frequently Asked Questions

How has Genprex's stock price performed in 2022?

Genprex's stock was trading at $1.31 at the start of the year. Since then, GNPX stock has increased by 5.3% and is now trading at $1.38.
View the best growth stocks for 2022 here

When is Genprex's next earnings date?

Genprex is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Genprex

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) announced its earnings results on Friday, May, 13th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03.
View Genprex's earnings history

Who are Genprex's key executives?

Genprex's management team includes the following people:
  • Mr. John Rodney Varner, Co-Founder, Chairman, Pres & CEO (Age 65, Pay $747.18k)
  • Mr. Ryan M. Confer M.S., Chief Financial Officer (Age 40, Pay $522.67k)
  • Ms. Catherine M. Vaczy Esq., Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer (Age 61, Pay $597.58k)
  • Dr. Hemant Kumar C.P.M., EMBA, Ph.D., Chief Manufacturing & Technology Officer (Age 59)
  • Ms. Kalyn Dabbs, Sr. Mang. of Communications & Marketing
  • Mr. David M. Schloss, Sr. VP of HR
  • Mr. Thomas C. Gallagher Esq., Sr. VP of Intellectual Property & Licensing
  • Dr. William E. Gannon Jr., Member of Clinical Advisory Board & VP of Regulatory Affairs
  • Dr. Mark S. Berger M.D., Chief Medical Officer (Age 67)
  • Mr. Greg Jancarik C.M.A., CPA, M.B.A., Corp. Controller

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

How do I buy shares of Genprex?

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $1.38.

How much money does Genprex make?

Genprex (NASDAQ:GNPX) has a market capitalization of $66.10 million.

How many employees does Genprex have?

Genprex employs 12 workers across the globe.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The official website for Genprex is www.genprex.com. The company can be reached via phone at (877) 774-4679 or via email at investors@genprex.com.

This page (NASDAQ:GNPX) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.